X CEPTOR THERAPEUTICS INC has a total of 35 patent applications. Its first patent ever was published in 2001. It filed its patents most often in WIPO (World Intellectual Property Organization), United States and Australia. Its main competitors in its focus markets organic fine chemistry, pharmaceuticals and measurement are PFIZER PHARMA, YASUMA TSUNEO and SPEEDEL EXPERIMENTA AG.
# | Country | Total Patents | |
---|---|---|---|
#1 | WIPO (World Intellectual Property Organization) | 10 | |
#2 | United States | 6 | |
#3 | Australia | 5 | |
#4 | EPO (European Patent Office) | 5 | |
#5 | Canada | 4 | |
#6 | Japan | 2 | |
#7 | Taiwan | 2 | |
#8 | Brazil | 1 |
# | Industry | |
---|---|---|
#1 | Organic fine chemistry | |
#2 | Pharmaceuticals | |
#3 | Measurement |
# | Technology | |
---|---|---|
#1 | Therapeutic chemical compounds | |
#2 | Heterocyclic compounds | |
#3 | Acyclic or carbocyclic compounds | |
#4 | Medical preparations | |
#5 | Analysing materials |
# | Name | Total Patents |
---|---|---|
#1 | Martin Richard | 24 |
#2 | Mohan Raju | 16 |
#3 | Wang Tie-Lin | 14 |
#4 | Flatt Brenton Todd | 11 |
#5 | Flatt Brenton T | 11 |
#6 | Gu Xiao-Hui | 9 |
#7 | Johnson Alan T | 9 |
#8 | Griffith Ronald | 8 |
#9 | Schweiger Edwin J | 5 |
#10 | Murphy Brett | 4 |
Publication | Filing date | Title |
---|---|---|
WO2005072731A1 | 3-phenyl-n- ((1, 3, 4) thiadiazol-2-yl) -acrylamide derivatives and related compounds as modulators of estrogen-related receptors for the treatment of e.g. cancer, rheumatoid arthritis or neurological disorders | |
WO2005047268A2 | Substituted pyrimidine compositions and methods of use | |
AU2004282162A1 | Bridged ring structures as pharmaceutical agents | |
US2005080111A1 | Modulators of LXR | |
AU2003301020A1 | Isoquinolinone derivatives and their use as therapeutic agents | |
TW200307684A | Azepinoindole and pyridoindole derivatives as pharmaceutical agents | |
AU2003228283A1 | Quinazolinone modulators of nuclear receptors | |
WO03059884A1 | Modulators of lxr | |
US6696473B2 | Heterocyclic modulators of nuclear receptors | |
US6924311B2 | Methods for affecting various diseases utilizing LXR compounds |